For: | O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021; 12(3): 164-182 [PMID: 33767972 DOI: 10.5306/wjco.v12.i3.164] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v12/i3/164.htm |
Number | Citing Articles |
1 |
Youyang Shi, Yuanyuan Wu, Feifei Li, Kexin Jiang, Xiaofang Fang, Yu Wang, Xiaoyun Song, Rui Wang, Lixin Chen, Jinzhou Zheng, Chunyu Wu, Yuenong Qin, Xiaofei Liu, Sheng Liu. Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer. Phenomics 2024; 4(1): 34 doi: 10.1007/s43657-023-00133-x
|
2 |
Luis Piedra-Delgado, Diego Chambergo-Michilot, Zaida Morante, Carlos Fairen, Fernando Jerves-Coello, Renato Luque-Benavides, Fresia Casas, Eduarda Bustamante, Cesar Razuri-Bustamante, J. Smith Torres-Roman, Hugo Fuentes, Henry Gomez, Alexis Narvaez-Rojas, Gabriel De la Cruz-Ku, Jhajaira Araujo, Divijendra Natha Reddy Sirigiri. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience. PLOS ONE 2024; 19(2): e0293833 doi: 10.1371/journal.pone.0293833
|
3 |
Harini Narasimhan, Francesca Ferraro, Andreas Bleilevens, Ralf Weiskirchen, Elmar Stickeler, Jochen Maurer. Tumor Necrosis Factor-α (TNFα) Stimulates Triple-Negative Breast Cancer Stem Cells to Promote Intratumoral Invasion and Neovasculogenesis in the Liver of a Xenograft Model. Biology 2022; 11(10): 1481 doi: 10.3390/biology11101481
|
4 |
Akhilandeshwari Ravichandran, James Monkman, Ahmed M. Mehdi, Tony Blick, Cameron Snell, Arutha Kulasinghe, Laura J. Bray. The in situ transcriptomic landscape of breast tumour-associated and normal adjacent endothelial cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024; 1870(2): 166985 doi: 10.1016/j.bbadis.2023.166985
|
5 |
Sibylle Loibl, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Aditya Bardia, Sara A. Hurvitz, Adam M. Brufsky, Kevin Kalinsky, Javier Cortés, Joyce A. O'Shaughnessy, Véronique Dieras, Lisa A. Carey, Luca Gianni, Mahdi Gharaibeh, Luciana Preger, See Phan, Lawrence Chang, Ling Shi, Martine J. Piccart. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European Journal of Cancer 2023; 178: 23 doi: 10.1016/j.ejca.2022.10.003
|
6 |
Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy. Molecular Diversity 2024; doi: 10.1007/s11030-024-10964-z
|
7 |
Marine C. N. M. Blackman, Tania Capeloa, Justin D. Rondeau, Luca X. Zampieri, Zohra Benyahia, Justine A. Van de Velde, Maude Fransolet, Evangelos P. Daskalopoulos, Carine Michiels, Christophe Beauloye, Pierre Sonveaux. Mitochondrial Protein Cox7b Is a Metabolic Sensor Driving Brain-Specific Metastasis of Human Breast Cancer Cells. Cancers 2022; 14(18): 4371 doi: 10.3390/cancers14184371
|
8 |
Wenlu Yan, Yu Li, Yiting Zou, Runqi Zhu, Ting Wu, Xujie Sun, Wenhui Yuan, Tianqun Lang, Qi Yin, Yaping Li. Breaking Tumor Immunosuppressive Network by Regulating Multiple Nodes with Triadic Drug Delivery Nanoparticles. ACS Nano 2023; 17(18): 17826 doi: 10.1021/acsnano.3c03387
|
9 |
Shom Goel, Antoinette R Tan, Hope S Rugo, Philippe Aftimos, Zoran Andrić, Andrew Beelen, Jingshan Zhang, John S Yi, Rajesh Malik, Joyce O’Shaughnessy. Trilaciclib Prior to Gemcitabine Plus Carboplatin for Metastatic Triple-Negative Breast Cancer: Phase III PRESERVE 2. Future Oncology 2022; 18(33): 3701 doi: 10.2217/fon-2022-0773
|
10 |
Sai Harshita Posani, Noelle E. Gillis, Carol A. Lange. Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 2024; 243: 106575 doi: 10.1016/j.jsbmb.2024.106575
|
11 |
Nevin Erk, Özgül Vural, Wiem Bouali, Asena Ayse Genc, Lalitha Gnanasekaran, Hassan Karimi-Maleh. Smart and sensitive nanomaterial-based electrochemical sensor for the determination of a poly (ADP-ribose) polymerase (PARP) inhibitor anticancer agent. Environmental Research 2023; 238: 117082 doi: 10.1016/j.envres.2023.117082
|
12 |
Shih-Hsuan Chan, Wen-Hung Kuo, Lu-Hai Wang. SCEL regulates switches between pro-survival and apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer. Journal of Biomedical Science 2023; 30(1) doi: 10.1186/s12929-023-00986-4
|
13 |
Hua Yang, Yongjun Liu. RETRACTED: Kinesin Family Member 2A Serves as a Potential Biomarker Reflecting More Frequent Lymph Node Metastasis and Tumor Recurrence Risk in Basal-Like Breast Cancer Patients. Frontiers in Surgery 2022; 9 doi: 10.3389/fsurg.2022.889294
|
14 |
Mohammad Amin Bazzazan, Pourya Fathollazadeh, Sanaz Keshavarz Shahbaz, Nima Rezaei. Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives. International Journal of Pharmaceutics 2024; 664: 124639 doi: 10.1016/j.ijpharm.2024.124639
|
15 |
Jaspreet Kaur, Darshan S. Chandrashekar, Zsuzsanna Varga, Bettina Sobottka, Emiel Janssen, Khanjan Gandhi, Jeanne Kowalski, Umay Kiraz, Sooryanarayana Varambally, Ritu Aneja. Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers. Genes 2023; 14(9): 1690 doi: 10.3390/genes14091690
|
16 |
Alejandra Estepa-Fernández, Alba García-Fernández, Araceli Lérida-Viso, Ángela Morellá-Aucejo, Juan José Esteve-Moreno, Juan F. Blandez, María Alfonso, Vicente Candela-Noguera, Gema Vivo-Llorca, Félix Sancenon-Galarza, Mar Orzáez, Ramón Martínez-Máñez. Engineering nanoparticle communication in living systems by stigmergy: An application to enhance antitumor therapy in triple-negative breast cancer. Nano Today 2023; 48: 101692 doi: 10.1016/j.nantod.2022.101692
|
17 |
Liyang Yin, Renxian Cao, Zhuoqing Liu, Gang Luo, Yu Li, Xiaolong Zhou, Xiguang Chen, Ying Wu, Jun He, Xuyu Zu, Yingying Shen. FUNDC2, a mitochondrial outer membrane protein, mediates triple-negative breast cancer progression via the AKT/GSK3β/GLI1 pathway. Acta Biochimica et Biophysica Sinica 2023; doi: 10.3724/abbs.2023142
|
18 |
Daire Hanna, Sophie Merrick, Aruni Ghose, Michael John Devlin, Dorothy D. Yang, Edward Phillips, Alicia Okines, Neha Chopra, Elisavet Papadimatraki, Kirsty Ross, Iain Macpherson, Zhuang Y. Boh, Caroline O. Michie, Angela Swampillai, Sunnia Gupta, Tim Robinson, Lewis Germain, Chris Twelves, Charlotte Atkinson, Apostolos Konstantis, Pippa Riddle, Nicola Cresti, Jay D. Naik, Annabel Borley, Amy Guppy, Peter Schmid, Melissa Phillips. Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer 2024; 130(12): 1916 doi: 10.1038/s41416-024-02685-9
|
19 |
Kitty Y. Wu, Kirsten M. Hayford, Robert J. Spinner. In search of zebras: Critical analysis of the rarity of perineural breast cancer spread to the brachial plexus in men. Journal of Plastic, Reconstructive & Aesthetic Surgery 2024; 88: 231 doi: 10.1016/j.bjps.2023.10.139
|
20 |
Ali Mussa, Hafeez Abiola Afolabi, Nazmul Huda Syed, Mustafa Talib, Ahmad Hafiz Murtadha, Khalid Hajissa, Noor Fatmawati Mokhtar, Rohimah Mohamud, Rosline Hassan. The NF-κB Transcriptional Network Is a High-Dose Vitamin C-Targetable Vulnerability in Breast Cancer. Biomedicines 2023; 11(4): 1060 doi: 10.3390/biomedicines11041060
|
21 |
Arupam Patra, Arisha Arora, Siddhartha Sankar Ghosh, Gurvinder Kaur Saini. Beauvericin Reverses Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through Regulation of Notch Signaling and Autophagy. ACS Pharmacology & Translational Science 2024; 7(9): 2878 doi: 10.1021/acsptsci.4c00370
|
22 |
Dandan Li, Yu Yao, Kun Wang, Chunyu Lei, Xianfeng Peng, Chengjian Cao, Ke Zhu, Ziyang Zhu, Fuqiang Shao. Targeted delivery of Saikosaponin A and doxorubicin via hyaluronic acid-modified ZIF-8 nanoparticles for TNBC treatment: Inhibiting metastasis and reducing cardiotoxicity. Biomaterials Advances 2025; 167: 214114 doi: 10.1016/j.bioadv.2024.214114
|
23 |
Tomohiro Tanaka, Tomokazu Ohishi, Masaki Saito, Manabu Kawada, Mika K. Kaneko, Yukinari Kato. TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2022; 41(1): 32 doi: 10.1089/mab.2021.0056
|
24 |
Aditya Bardia, Ian E. Krop, Takahiro Kogawa, Dejan Juric, Anthony W. Tolcher, Erika P. Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I. Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P. Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of Clinical Oncology 2024; 42(19): 2281 doi: 10.1200/JCO.23.01909
|
25 |
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics 2023; 15(7): 1796 doi: 10.3390/pharmaceutics15071796
|
26 |
Chinedu C. Okorafor, Sanjana Shastri, Ke Wen, Eno E. Ebong. Mechanisms of triple‐negative breast cancer extravasation: Impact of the physical environment and endothelial glycocalyx. The FASEB Journal 2024; 38(13) doi: 10.1096/fj.202400380R
|
27 |
Yongxiu Huang, Anqi Zeng, Linjiang Song. Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1255820
|
28 |
Md Abdus Subhan, Farzana Parveen, Hassan Shah, Satya Siva Kishan Yalamarty, Janaína Artem Ataide, Valdimir P. Torchilin. Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers 2023; 15(8): 2204 doi: 10.3390/cancers15082204
|
29 |
Ji Hyeon Kim, Jung Min Park, Eunsun Jung, Jieun Lee, Jiyou Han, Yoon-Jae Kim, Ji Young Kim, Jae Hong Seo, Jong Seung Kim. A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis. Biomaterials 2022; 289: 121781 doi: 10.1016/j.biomaterials.2022.121781
|
30 |
Alejandra Estepa-Fernández, Alba García-Fernández, Araceli Lérida-Viso, Juan F. Blandez, Irene Galiana, Félix Sancenon-Galarza, Mar Orzáez, Ramón Martínez-Máñez. Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. Pharmacological Research 2023; 187: 106628 doi: 10.1016/j.phrs.2022.106628
|
31 |
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles. MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell Death Discovery 2024; 10(1) doi: 10.1038/s41420-024-02128-7
|
32 |
Amal Qattan, Taher Al-Tweigeri, Kausar Suleman, Wafa Alkhayal, Asma Tulbah. Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC). Cancers 2024; 16(17): 3057 doi: 10.3390/cancers16173057
|
33 |
Yun-Chi Wang, Jie-Long He, Chung-Lin Tsai, Huey-En Tzeng, Wen-Shin Chang, Shih-Han Pan, Li-Hsiou Chen, Chen-Hsien Su, Jiunn-Cherng Lin, Chih-Chiang Hung, Da-Tian Bau, Chia-Wen Tsai. The Contribution of Tissue Inhibitor of Metalloproteinase-2 Genotypes to Breast Cancer Risk in Taiwan. Life 2023; 14(1): 9 doi: 10.3390/life14010009
|
34 |
Versha Pleasant. A Public Health Emergency. Obstetrics and Gynecology Clinics of North America 2024; 51(1): 69 doi: 10.1016/j.ogc.2023.11.001
|
35 |
Anna Wawruszak, Marta Halasa, Estera Okon, Wirginia Kukula-Koch, Andrzej Stepulak. Valproic Acid and Breast Cancer: State of the Art in 2021. Cancers 2021; 13(14): 3409 doi: 10.3390/cancers13143409
|
36 |
Thodoris Sklias, Vasileios Vardas, Evangelia Pantazaka, Athina Christopoulou, Vassilis Georgoulias, Athanasios Kotsakis, Yiannis Vasilopoulos, Galatea Kallergi. PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs. Cancers 2022; 14(7): 1731 doi: 10.3390/cancers14071731
|
37 |
Adrienn Molnár, Gabriel Stefan Horkovics-Kováts, Nóra Kucsma, Zsuzsanna Szegő, Boglárka Tauber, Attila Egri, Zoltán Szkupien, Bálint András Deák, James S. McKenzie, Julianna Thuróczy, Richard Schäffer, Gitta Schlosser, Gergely Szakács, Júlia Balog. Characterisation of Canine and Feline Breast Tumours, Their Metastases, and Corresponding Primary Cell Lines Using LA-REIMS and DESI-MS Imaging. International Journal of Molecular Sciences 2024; 25(14): 7752 doi: 10.3390/ijms25147752
|
38 |
Manosi Banerjee, V. Devi Rajeswari. A novel cross-communication of HIF-1α and HIF-2α with Wnt signaling in TNBC and influence of hypoxic microenvironment in the formation of an organ-on-chip model of breast cancer. Medical Oncology 2023; 40(8) doi: 10.1007/s12032-023-02112-8
|
39 |
Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen. A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments. International Journal of Cancer 2023; 152(10): 2134 doi: 10.1002/ijc.34424
|
40 |
Deyi Zhao, Zhe Li, Ding-Kun Ji, Qian Xia. Recent Progress of Multifunctional Molecular Probes for Triple-Negative Breast Cancer Theranostics. Pharmaceutics 2024; 16(6): 803 doi: 10.3390/pharmaceutics16060803
|
41 |
Luca Filippi, Luca Urso, Cristina Ferrari, Priscilla Guglielmo, Laura Evangelista. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. European Journal of Nuclear Medicine and Molecular Imaging 2024; doi: 10.1007/s00259-024-06866-9
|
42 |
Ayesha Khan, Md Abu Sayed, Khaled Hosny, Godwins Echejoh, Santhi Kumar. Incidentaloma on Staging CT Revealed to Be Breast to Renal Tumour-to-Tumour Metastasis. Cureus 2023; doi: 10.7759/cureus.45658
|
43 |
Maria Rosaria Valerio, Pietro Spadaro, Concetta Arcanà, Nicolò Borsellino, Calogero Cipolla, Paolo Vigneri, Dario Piazza, Vittorio Gebbia. Oral Vinorelbine and Capecitabine as First-Line Therapy in Metastatic Breast Cancer: A Retrospective Analysis. Future Science OA 2021; 7(10) doi: 10.2144/fsoa-2020-0095
|
44 |
Soyoung Kim, Ilseob Choi, Ik-Hwan Han, Hyunsu Bae. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer. International Journal of Molecular Sciences 2022; 23(24): 15751 doi: 10.3390/ijms232415751
|
45 |
Débora Ferreira, Cátia Santos-Pereira, Marta Costa, Julieta Afonso, Sujuan Yang, Janine Hensel, Kathleen M. McAndrews, Adhemar Longatto-Filho, Rui Fernandes, Joana B. Melo, Fátima Baltazar, João N. Moreira, Raghu Kalluri, Ligia R. Rodrigues. Exosomes modified with anti-MEK1 siRNA lead to an effective silencing of triple negative breast cancer cells. Biomaterials Advances 2023; 154: 213643 doi: 10.1016/j.bioadv.2023.213643
|
46 |
Luyao Dai, Hanxiao Cui, Yuanhang Bao, Liqun Hu, Zhangjian Zhou, Meng Wang, Shuai Lin, Hao Wu, Huafeng Kang, Xiaobin Ma. The relationship between immediate postmastectomy reconstruction modalities and survival benefits in patients with triple negative breast cancer. Cancer Medicine 2023; 12(3): 2782 doi: 10.1002/cam4.5166
|
47 |
Fu-Ying Qin, Yan-Yi Chen, Jiao-Jiao Zhang, Yong-Xian Cheng. Meroterpenoid Dimers from Ganoderma Mushrooms and Their Biological Activities Against Triple Negative Breast Cancer Cells. Frontiers in Chemistry 2022; 10 doi: 10.3389/fchem.2022.888371
|
48 |
Pan Wang, Wenju Chen, Yaqiong Zhang, Qianyi Zhong, Zhaoyun Li, Yichao Wang. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition. Molecular Biology Reports 2022; 49(4): 2711 doi: 10.1007/s11033-021-07080-8
|
49 |
Aditya Bardia, Lajos Pusztai, Kathy Albain, Eva Maria Ciruelos, Seock-Ah Im, Dawn Hershman, Kevin Kalinsky, Claudine Isaacs, Delphine Loirat, Laura Testa, Eriko Tokunaga, Jiong Wu, Hannah Dry, William Barlow, Robert Kozarski, Micah Maxwell, Nadia Harbeck, Priyanka Sharma. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology 2024; 16 doi: 10.1177/17588359241248336
|
50 |
Zhi Li, Chloe Nguyen, Hongje Jang, David Hoang, SoeSu Min, Ellen Ackerstaff, Jason A. Koutcher, Lingyan Shi. Multimodal imaging of metabolic activities for distinguishing subtypes of breast cancer. Biomedical Optics Express 2023; 14(11): 5764 doi: 10.1364/BOE.500252
|
51 |
Lisa Hong, Dennis C. Braden, Yaoning Zhao, John J. Skoko, Fei Chang, Steven R. Woodcock, Crystall Uvalle, Allison Casey, Katherine Wood, Sonia R. Salvatore, Alparslan Asan, Trey Harkness, Adeola Fagunloye, Mortezaali Razzaghi, Adam Straub, Maria Spies, Daniel D. Brown, Adrian V. Lee, Francisco Schopfer, Bruce A. Freeman, Carola A. Neumann. Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies. Redox Biology 2023; 66: 102856 doi: 10.1016/j.redox.2023.102856
|
52 |
Manosi Banerjee, Vijayarangan Devi Rajeswari. Critical Review on the Different Roles of Exosomes in TNBC and Exosomal-Mediated Delivery of microRNA/siRNA/lncRNA and Drug Targeting Signalling Pathways in Triple-Negative Breast Cancer. Molecules 2023; 28(4): 1802 doi: 10.3390/molecules28041802
|
53 |
Juvin Ann Thomas, Athira Gireesh Gireesh Moly, Hima Xavier, Priya Suboj, Amit Ladha, Gaurav Gupta, Santosh Kumar Singh, Partha Palit, Suboj Babykutty. Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1063051
|